Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
Unternehmens-codeALUR_t
Name des UnternehmensAllurion Technologies Inc
IPO-datumMar 29, 2021
Gegründet am2023
CEODr. Shantanu Gaur, M.D.
Anzahl der mitarbeiter- -
Wertpapierart- -
Geschäftsjahresende- -
Addresse11 Huron Dr Ste 200
StadtNATICK
Börse- -
LandUnited States of America
Postleitzahl01760
Telefon15086474000
Websitehttps://www.allurion.com/en
Unternehmens-codeALUR_t
IPO-datumMar 29, 2021
Gegründet am2023
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten